These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 1981012)
21. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Maulard C; Richaud P; Droz JP; Jessueld D; Dufour-Esquerré F; Housset M Cancer Chemother Pharmacol; 1995; 36(3):259-62. PubMed ID: 7540120 [TBL] [Abstract][Full Text] [Related]
22. Clinical use of somatostatin analogues (Sandostatin, SMS 20l-995). Proceedings of a symposium. Amsterdam, November 14, 1986. Acta Endocrinol Suppl (Copenh); 1987; 286():1-66. PubMed ID: 2892333 [No Abstract] [Full Text] [Related]
23. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Emons G; Schally AV Hum Reprod; 1994 Jul; 9(7):1364-79. PubMed ID: 7962452 [TBL] [Abstract][Full Text] [Related]
24. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Figg WD; Thibault A; Cooper MR; Reid R; Headlee D; Dawson N; Kohler DR; Reed E; Sartor O Cancer; 1995 Apr; 75(8):2159-64. PubMed ID: 7535186 [TBL] [Abstract][Full Text] [Related]
25. Management of breast cancer: is there a role for somatostatin and its analogs? Boccardo F; Amoroso D Chemotherapy; 2001; 47 Suppl 2():62-77. PubMed ID: 11275703 [TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Pinski J; Reile H; Halmos G; Groot K; Schally AV Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203 [TBL] [Abstract][Full Text] [Related]
27. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Öberg K; Lamberts SW Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899 [TBL] [Abstract][Full Text] [Related]
28. Radiolabelled somatostatin analog therapy in prostate cancer: current status and future directions. Liu Y Cancer Lett; 2006 Jul; 239(1):21-6. PubMed ID: 16126334 [TBL] [Abstract][Full Text] [Related]
29. Treatment of inappropriate secretion of thyrotropin with somatostatin analog SMS 201-995. Beck-Peccoz P; Medri G; Piscitelli G; Mariotti S; Bertoli A; Barbarino A; Rondena M; Martino E; Pinchera A; Faglia G Horm Res; 1988; 29(2-3):121-3. PubMed ID: 2900192 [TBL] [Abstract][Full Text] [Related]
30. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Setyono-Han B; Henkelman MS; Foekens JA; Klijn GM Cancer Res; 1987 Mar; 47(6):1566-70. PubMed ID: 2880660 [TBL] [Abstract][Full Text] [Related]
31. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528 [TBL] [Abstract][Full Text] [Related]
32. Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies. Klijn JG; Setyono-Han B; Bakker GH; van der Burg ME; Bontenbal M; Peters HA; Sieuwerts AM; Berns PM; Foekens JA J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1089-95. PubMed ID: 1981013 [TBL] [Abstract][Full Text] [Related]
33. Differential effects of LHRH and somatostatin analogs on human breast cancer. Brower ST; Schally AV; Redding TW; Hollander VP J Surg Res; 1992 Jan; 52(1):6-14. PubMed ID: 1347798 [TBL] [Abstract][Full Text] [Related]
34. Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: implications for the treatment of apudomas. Ellison EC; O'Dorisio TM; Sparks J; Mekhjian HS; Fromkes JJ; Woltering EA; Carey LC Surgery; 1986 Aug; 100(2):437-44. PubMed ID: 2426819 [TBL] [Abstract][Full Text] [Related]
35. Somatostatin analogs in the management of gastrointestinal tumors. Lamberts SW Horm Res; 1988; 29(2-3):118-20. PubMed ID: 2900191 [TBL] [Abstract][Full Text] [Related]
36. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045 [TBL] [Abstract][Full Text] [Related]
37. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824 [TBL] [Abstract][Full Text] [Related]
38. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Modlin IM; Pavel M; Kidd M; Gustafsson BI Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567 [TBL] [Abstract][Full Text] [Related]